MAXIDEX
As listed in the register: MAXIDEX
0.1 % · suspension
- Prescription only
- Eyes and ears
- Active substance
- Dexamethasone
- Used in
- Eyes and ears
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (dexamethasone). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Dexamethasone is a corticosteroid with anti-inflammatory effects and low mineralocorticoid activity.
The precise mechanism of action in multiple myeloma is unknown.
Dexamethasone is metabolized by CYP3A4.
Less than 10% of dexamethasone is excreted in the urine.
Effect of Food A high-fat, high-calorie (total 800-1000 calories: approximately 60% from fat, 25% from carbohydrate and 15% from protein) meal had no effect on AUC inf and decreased C max by 23% of a single 20 mg dose of HEMADY.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-09
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (dexamethasone). It describes the substance, not this Bulgarian product — its uses and doses can differ.
- HEMADY is contraindicated in patients with: Hypersensitivity to dexamethasone, or any of the excipients.
- Rare instances of anaphylactic reactions have been reported [see Adverse Reactions ( 6 ), Description ( 11 )].
- Systemic fungal infections.
- Corticosteroids may exacerbate systemic fungal infections [see Warnings and Precautions ( 5.2 )]..
The most common adverse reactions are cardiovascular, dermatologic, endocrine, fluid and electrolyte disturbances, gastrointestinal, metabolic, musculoskeletal, neurological/psychiatric, ophthalmic, abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, and weight gain.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
BulgariaNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Dexamethasone |
| Used in | Eyes and ears |
| Strength | 0.1 % |
| Form | suspension |
| Classification | S01BA01 · Eyes and ears |
| Route | ophthalmic |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 00042560 |
| DPD drug code | 2620 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- suspension1 products
- 0.1 %
- ointment1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.